Ionis Pharmaceuticals secured a wider FDA approval for Tryngolza (olezarsen), expanding the therapy’s use into adults with severe hypertriglyceridemia. The approval follows phase III data previously reported by the company, and it moves Tryngolza beyond rare “FCS” use into a broader cardiometabolic indication. In a related regulatory readout, a separate summary noted Tryngolza’s earlier approval positioned it as the first therapy for severe hypertriglyceridemia—an indication linked to acute pancreatitis risk. The label expansion increases commercial scope for Ionis’ antisense portfolio and signals growing FDA acceptance for targeted nucleotide-based therapies in metabolic disease.